Answers are grounded in this paper and cite their sources.
Background Finerenone was approved for the treatment of type 2 diabetes patients with chronic kidney disease. However, the post-marketing safety of finerenone in the real world is unknown.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: